Resmetirom is currently in Phase 3 clinical development

Compound/indication	Clinical study	Pre-clinical	Phase 1	Phase 2	Phase 3	Description
Resmetirom (MGL-3196) THR-β agonist **Treatment of NASH**	**Phase 2 MGL-3196-05** NCT02912260		**Completed**			■ MRI-PDFF, liver biopsy: endpoints achieved[1,2] • 36 weeks with 36-week OLE
	Phase 3 MAESTRO-NASH NCT03900429		**Recruiting**			■ Treatment of NASH with F2-3:[3] • 52-week Phase 3; 54-month outcomes • Serial liver biopsy
	Phase 3 MAESTRO-NAFLD-1 (presumed NASH) NCT04197479		**Ongoing**			■ Treatment of NASH:[3] • *Safety, lipids and NASH biomarker and imaging study* • *52 weeks* • *Enrollment of double-blind arms completed* • *Open-label 100 mg arm; includes NASH cirrhotics*

MAESTRO Phase 3 studies provide a comprehensive data set to support efficacy and safety, consistent with regulatory requirements to support accelerated approval of Resmetirom for treatment of patients with NASH with significant liver fibrosis

F, fibrosis stage; MRI-PDFF, magnetic resonance imaging-derived proton density fat fraction; NASH, non-alcoholic steatohepatitis; OLE, open-label extension; THR-β, thyroid hormone receptor β. 1. Harrison SA, et al. *Lancet*. 2019;394(10213):2012-24; 2. Harrison SA, et al. *Hepatol Commun*. 2021;0:1-16; 3. ClinicalTrials.gov. NCT03900429 and NCT04197479. 2020 and 2021. Available at: https://clinicaltrials.gov [accessed Sept 2021].

Madrigal Pharmaceuticals